Journals / Journal of the Turkish-German Gynecological Association / 2010 / Cilt: 11 - Sayı: 2

Umbilikal kordon kanı toplanmasının altında yatan gerçek

The rationale behind collecting umbilical cord blood

Pages
99–101
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To improve availability of stem cells to a broader community, efforts should be undertaken to collect cord blood and expectant parents should be properly informed of their options with regard to cord blood banking.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Umbilical cord blood (UCB) is an increasingly important and rich source of stem cells.
📊
Key Findings & Data:Even though almost 80 diseases are treatable with cord blood stem cells, 97 percent of cord blood is still disposed of after birth and lost for patients in need!
💡
Conclusion & Impact:To improve availability of stem cells to a broader community, efforts should be undertaken to collect cord blood and expectant parents should be properly informed of their options with regard to cord blood banking.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Umbilical cord blood (UCB) is an increasingly important and rich source of stem cells. These cells can be used for the treatment of many diseases, including cancers and immune and genetic disorders. For patients for whom no suitable related donor is available, this source of hematopoietic stem cells offers substantial advantages, notably the relative ease of procurement, the absence of risk to the donor, the small likelihood of transmitting clinically important infections, the low risk of severe graft-versus-host disease (GVHD) and the rapid availability of placental blood for transplantation centers. Even though almost 80 diseases are treatable with cord blood stem cells, 97 percent of cord blood is still disposed of after birth and lost for patients in need! To improve availability of stem cells to a broader community, efforts should be undertaken to collect cord blood and expectant parents should be properly informed of their options with regard to cord blood banking.

Özet

Umbilikal kordon kanı kök hücre zengin bir kök hücre kaynağıdır ve önemi gittikçe artmaktadır. Bu hücreler kanser, immun ve genetik birçok hastalığın tedavisinde kullanılmaktadırlar. Uygun donor bulunamayan hastalar için bu hemopoetik kök hücre kaynağı birçok avantajlar sunar. Bunlar; işleme için kolaylık, donor bulunmama riskinin ortadan kalkması, klinik önemi olan enfeksiyon hastalıklarının bulaşma oranının düşük olması, greft reddi oranının az olması ve plasenta kanının tarnsplantasyon merkezlerine kolayca ulaştırılması gibi. Kordon kanındaki kök hücreler ile şu an yaklaşık olarak 80 kadar hastalık tedavi edilebilirken, ne yazık ki kordon kanlarının %97’si hala atılmakta ve hastalar tedavi şanslarını yitirmektedirler. Kök hücrelerin bulunabilirliğini arttırmak ve tüm topluma ulaştırmak için, kordon kanını toplamak ve çiftleri kordon kanı bankacılığı hakkında yeterli bilgilendirmek için çaba harcanmalıdır.

🔖

Cite This Article

ZECH, N. H., BROER, N., RİBİTSCH, I., ZECH, M. H., PREİSEGGER, K., ERTAN, K., BROER, K. (2022). Umbilikal kordon kanı toplanmasının altında yatan gerçek. Journal of the Turkish-German Gynecological Association, Cilt: 11 - Sayı: 2, 99–101. https://ajindex.com/articles/567808

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Karanes C, Confer D, Walker T, Askren A, Keller C. Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program. Oncology (Williston Park) 2003; 17:1036-68, 1043-104, 1164-7
  2. Wagner JE, Rosenthal J, Sweetman R. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versushost disease. Blood 1996; 88: 795-802. 3.
  3. Frey MA, Guess C, Allison J. Umbilical cord stem cell transplantation. Semin Oncol Nurs 2009; 25: 115-9
  4. Sierra J, Martino R, Sánchez B, Pinana JL, Valcarcel D, Brunet S. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant. 2008; 41: 425-37
  5. Johansen KA, Schneider JF, McCaffree MA. Efforts of the United States’ National Marrow Donor Program and Registry to improve utilization and representation of minority donors. Transfus Med. 2008; 18: 250-9
  6. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-66
  7. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placentalblood transplants from unrelated donors. N Engl J Med. 1998; 339: 1565-77
  8. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000; 342: 1846-54
  9. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989; 321: 1174-8.